Document Type

Poster

Publication Date

2024

Publication Title

Proceedings of the 5th International Electronic Conference on Foods

Conference Name

The 5th International Electronic Conference on Foods, 28-30 October 2024, Online

Abstract

Introduction: a loss of intestinal barrier function, inflammation, and an elevated expression of epithelial heat shock protein 60 (Hsp60) are features of an inflamed bowel. Probiotics have been used to alleviate colitis-induced pathologies, but offer poor adhesion and adaptation to the diseased gut. We hypothesize that enhancing probiotic adhesion in the inflamed bowel may ameliorate such pathologies. Listeria adhesion protein (LAP; 94-kDa acetaldehyde alcohol dehydrogenase) aids Listeria attachment to the epithelial cells by interacting with the mammalian receptor Hsp60. Bioengineered Lactobacillus casei probiotics (BLPs) expressing LAP showed strong interaction with epithelial Hsp60, a high immunomodulatory response, and sustained epithelial barrier integrity.

Method: Dextran sodium sulfate (DSS)-treated mice were fed with BLP (1x1010 CFU/mL) for 10 days.

Results: DSS (2%, 7days)-fed mice treated with BLP showed a > 50% reduction in FITC-labeled 4 kDa dextran (FD4; epithelial permeability marker) translocation compared to the control groups. BLP-fed DSS-treated mice gained 3% body weight and conferred a 40% reduction in disease activity index (DAI) and inflammatory response compared to the control. BLP treatment restored fecal consistency to Type 3, 4 (Bristol scoring) within 9 days of feeding, while the controls failed. The colon showed visible damage (shortening), wall thickening, fragile tissue, and mucus accumulation in control mice, while the cecum and colon of BLP-fed mice appeared healthy. The microbiome data show a partial restoration of diversity and richness, primarily a distinct subpopulation fed with the BLPs. Myosin light chain kinase (MLCK, tight junction modulator) knock-out (KO) mice have increased resistance to DSS-induced colitis. Post-DSS treatment, BLP-fed MLCK mice improved weight gain, restored fecal consistency, and recuperated colonic health compared to the control groups, despite enhanced colitis symptoms.

Conclusions: Our BLPs offer promising results in alleviating mammalian gut inflammation and can be implemented as a food additive to improve gut health.

Comments

Conference Poster.

Rights

© The Authors 2024

"No special permission is required to reuse all or part of article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. Reuse of an article does not imply endorsement by the authors or MDPI. Furthermore, no special permission is required for authors to submit their work to external repositories. This policy extends to all versions of a paper: submitted, accepted, and published."

Published under the terms of a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Original Publication Citation

Gallina, N., Nathan, V., Krishnakumar, A., Liu, D., Drolia, R., Tardi, N. I., Fu, Y., Samadar, M., Tenguria, S., Cai, A., Centeno-Martinez, R. E., Johnson, T. A., Cox, A., Reddivari, L., Applegate, B., Bai, X., Xu, L., Tanjore, D., Vemulapalli, R.,…Bhunia, A. K. (2024). Receptor-targeted next-generation probiotics ameliorate mammalian colitis [Poster presentation]. The 5th International Electronic Conference on Foods, Online. https://sciforum.net/paper/view/19750

ORCID

0000-0002-8405-2961 (Drolia)

Download

Share

 
COinS